AEROVATE THERAPEUTICS INC (AVTE)
US0080641071 - Common Stock
We assign a fundamental rating of 2 out of 10 to AVTE. AVTE was compared to 575 industry peers in the Biotechnology industry. AVTE has a great financial health rating, but its profitability evaluates not so good. AVTE is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year AVTE has reported negative net income.
AVTE had a negative operating cash flow in the past year.
In the past 5 years AVTE always reported negative net income.
AVTE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -78.73%, AVTE is doing worse than 70.77% of the companies in the same industry.
Looking at the Return On Equity, with a value of -93.15%, AVTE is in line with its industry, outperforming 46.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -78.73% | ||
| ROE | -93.15% | ||
| ROIC | N/A |
ROA(3y)-36.82%
ROA(5y)-82.65%
ROE(3y)-41%
ROE(5y)-258.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AVTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AVTE has more shares outstanding than it did 1 year ago.
There is no outstanding debt for AVTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
AVTE has an Altman-Z score of -2.34. This is a bad value and indicates that AVTE is not financially healthy and even has some risk of bankruptcy.
AVTE has a Altman-Z score (-2.34) which is in line with its industry peers.
There is no outstanding debt for AVTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.34 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
AVTE has a Current Ratio of 6.51. This indicates that AVTE is financially healthy and has no problem in meeting its short term obligations.
AVTE's Current ratio of 6.51 is fine compared to the rest of the industry. AVTE outperforms 64.44% of its industry peers.
AVTE has a Quick Ratio of 6.51. This indicates that AVTE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.51, AVTE is in the better half of the industry, outperforming 64.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.51 | ||
| Quick Ratio | 6.51 |
3. Growth
3.1 Past
AVTE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.77%.
EPS 1Y (TTM)-20.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -4.03% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1.36%
EPS Next 2Y28.31%
EPS Next 3Y15.78%
EPS Next 5Y-4.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AVTE. In the last year negative earnings were reported.
Also next year AVTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as AVTE's earnings are expected to grow with 15.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.31%
EPS Next 3Y15.78%
5. Dividend
5.1 Amount
No dividends for AVTE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AEROVATE THERAPEUTICS INC
NASDAQ:AVTE (9/27/2024, 8:00:00 PM)
After market: 2.06 0 (0%)2.06
-0.02 (-0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap59.47M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -78.73% | ||
| ROE | -93.15% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.51 | ||
| Quick Ratio | 6.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-20.77%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y1.36%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y